ClinicalTrials.gg
RecruitingNCT04155606CAMUpdated Jul 28, 2025

Comprehensive Aneurysm Management Trial

An interventional study of microsurgery; endovascular interventions in Saccular Aneurysm, Intracranial Aneurysm and Unruptured Cerebral Aneurysm, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Primary conditionIntracranial AneurysmRegistry: AneurysmReclassifiedWhy we changed it
Registry
Aneurysm — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intracranial Aneurysm
Why
  1. The study's listed conditions name Intracranial Aneurysm, a narrower term within Aneurysm.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM) — 2 open to participants now, 3 under way, none of them phase 3. Intracranial Aneurysm · Centre hospitalier de l'Université de Montréal (CHUM).

Started
2020
the only one that year
No phase
8 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM), this one is the only one that started in 2020, is one of 8 with no phase, and was the 10th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

2 of the 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM) are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM), or all of them as a file.
02

Study summary

The uncertainty regarding the management of Unruptured Intracranial Aneurysms (UIAs) has not progressed in the last 30 years. The fundamental ethical basis for this study is that physicians should only offer a risky preventive treatment when it has been shown to be beneficial. Before that, such treatment should be offered as an RCT. The CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation.

The principal questions to be addressed are :

  1. do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management?
  2. when patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management? The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: the 10 year combined neurological morbidity and mortality (mRS>2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment.

This study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple RCTs whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. Patients will be followed for 10 years according to a standard of car follow-up schedule.

The primary outcome is survival without neurological dependency (mRS\<3) at 10 years.

The secondary outcomes are:

  1. the incidence of SAH during follow-up and related morbidity and mortality;
  2. the morbidity and mortality related to endovascular or surgical treatment of the UIA at one year;
  3. overall mortality at 1, 5 and 10 years;
  4. overall morbidity (mRS>2) at 1, 5 and 10 years;
  5. length of hospitalization;
  6. discharge to location other than home
Read the detailed description

The best management of patients with unruptured intracranial aneurysms is currently uncertain.

The time-honored approach to treating UIAs is with microsurgical clipping, Surgical clipping is widely considered to be a safe, durable means to treat UIAs. In recent years, endovascular treatment (EVT) has increasingly replaced surgical clipping. The efficacy of EVT in the prevention of SAH remains unknown. EVT is reputed to be potentially less effective than surgery because of long term angiographic recurrences. Neither surgery nor EVT have been shown superior to conservative management. Yet, both endovascular and surgical treatment are used every day in a large number of patients, without evidence they are doing more good than harm, and without evidence that one is better than the other.

There is currently no scientific evidence to support treatment of UIAs and there are no well-accepted guidelines. The overall annual rupture risk for conservatively managed lesions remains \~1-2% over a follow-up of 6-9 years, likely an underestimate. There is currently no all-inclusive care trial framework for UIA patients. There are also no randomized trials currently comparing active and conservative management for UIAs.

The uncertainty regarding the management of UIAs has not progressed in the last 30 years. Avoiding iatrogenia and the consequences of over-diagnosis is an increasingly important public health goal. In the spirit of care trials, this CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation.

Main objectives

  1. To provide a care research framework to manage all patients with UIAs.
  2. For patients for whom conservative management is contemplated, to validate previous observational studies claiming rupture risks are very low. This registry could be used in the future to recruit patients in trials assessing the potential value of imaging follow-up studies or trials assessing pharmacological prevention of ruptures (such as ASA or statins).
  3. For each patient for whom curative treatment is contemplated, to provide a 50% chance of being spared a potentially useless or harmful treatment.
  4. For each patient for whom surgical clipping is contemplated, to provide a 50% chance of being offered a less invasive alternative.

Principal questions to be addressed:

  1. Can a care trial context assist clinicians and patients manage the UIA dilemma?
  2. When conservative management is contemplated, is the risk of rupture as low as unvalidated observational studies currently suggest?
  3. Do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management? More specifically:

    3.1 When active endovascular treatment is contemplated, do patients with UIAs have a better long-term clinical outcome with endovascular or conservative management? 3.2 When active surgical treatment is contemplated, do patients with UIAs have a better long-term clinical outcome with surgical or conservative management? 3.3 When active treatment is contemplated, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with (surgical/endovascular) or conservative management?

  4. When patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management?

Study design This study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple clinical care trials whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. A non-invasive (MRA or CTA) or catheter angiogram and a baseline CT-scan or MRI of the brain are required to enter the study. These studies should demonstrate the unequivocal presence of a saccular aneurysm, not recently ruptured (> 4 weeks since the last SAH). If they accept, all subjects will be registered, and when eligible, included in a specific randomized trial using the algorithm below which includes a combination of clinical judgment and randomized allocation. Conventional randomization will be performed whenever and wherever possible. A double consent pre-randomization design is possible wherever the method is accepted by the local IRB.

Planned algorithm for managing patients The algorithmic process combining clinical judgment and randomized allocation will proceed by asking the following questions to the treating physicians.

Q1: Is the patient being considered for treatment? Possible answers: YES or NO.

If the clinician selects NO, the patient will be included in the observational registry. If YES, the following question will be:

Q2: What treatment option is being considered for this patient? Clinicians will use clinical judgment to select one of three options: endovascular, surgical, or they will select that either treatment is reasonable.

Then comes the most important question:

Q3: Is conservative management a reasonable alternative given the lack of evidence that treatments are beneficial? Potential answers are YES or NO. If NO, they will be included in the CURES trial or in of the 2 treatment registries (surgical or endovascular). If YES, they will be included in the appropriate randomized trial (according to the answer to question 2) that compares endovascular to conservative management (TEAM, or trial on endovascular aneurysm management), surgical to conservative management (TSAM, or Trial on Surgical Aneurysm Management), or they will be included in the TOES arm (Trial on Observational, Endovascular or Surgical management), with potential for a second randomization, comparing surgical to endovascular treatment.

Hypotheses:

The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: The 10 year combined neurological morbidity and mortality (mRS >2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment.

Outcomes The primary outcome is survival without neurological dependency (mRS\<3) at 10 years.

Secondary outcome measures are needed to monitor patient outcomes during the duration of the trial.

Secondary outcomes will be: 1/ The incidence of SAH during follow-up and related morbidity and mortality; 2/ The morbidity and mortality related to EVT or surgical treatment of the UIA at one year; 3/ Overall mortality at 1, 5 and 10 years; 4/ Overall morbidity (mRS>2) at 1, 5 and 10 years; 5/ Length of hospitalization; 6/ Discharge to location other than home.

This pragmatic care trial has been designed to potentially include all patients with UIAs. Inclusion criteria are as broad as possible and exclusions as few as possible.

Frequency and duration of follow-up All the investigations proposed in the UIA care trial constitute part of routine, standard care in the treatment of unruptured intracranial aneurysms.

Patients who undergo treatment will be seen in clinic at approximately 6-12 weeks after treatment as part of routine follow-up care. Patients will be followed with another routine clinic visit at one year, and at 5 and 10 years thereafter. All treated patients will have non-invasive imaging (CTA or MRA) at 12 ± 2 months post-treatment to determine the presence of a major, saccular aneurysm recurrence.

Number of patients To assess whether the 10 year combined neurological morbidity and mortality (mRS >2) will be reduced from 24% to 16% with active treatment (beta 80%; alpha 0.048) will require at least 961 patients (836 plus 15% losses to FU and cross-overs).

Planned Statistical Analyses The 4 stratified trial arms (TSAM, TEAM II, TOES, and CURES) and the registries will be analyzed separately. Combined exploratory analyses will also be performed, looking for differences in group characteristics and in treatment outcomes between RCTs and registries, attempting to better understand the scope and limits of trial results. As with any trials of surgery, early risks may be followed by later benefit. Therefore the hazard ratio will be unfavorable during the recruitment years, while interventions are being performed. Initially, the DSMC will assure that treatment-related complications and hemorrhagic events are within confidence intervals compatible with a safe and meaningful trial. In order to describe how and when hemorrhagic events occur, analyses will include Kaplan-Meyer life-table methods to assess the 1, 5-, and 10-year survival, and survival without hemorrhage, among all those allocated immediate treatment (including the few who did not undergo it) and all those allocated deferral of any intervention (including the few who will eventually be treated). The 'survival' functions will be compared graphically and using a log-rank statistic. The main statistical tests will involve comparisons between the probabilities of mortality and morbidity-mortality 1/ from hemorrhage, excluding peri-operative complications, 2/ from hemorrhage or from complications of treatment, or 3/ comparisons of the 1, 5 and 10-year probabilities of combined disease/treatment-related mortality/morbidity, in the absence of other causes of death or disability. Descriptive statistics will be done on demographic variables and potential risk factors to compare the groups at baseline. Means, standard deviations and range will be presented for quantitative variables such as size of aneurysms and frequency tables for categorical variables (such as number of patients with a previous history of SAH, or multiple aneurysms). Statistics will be broken down by center and by treatment arm. Comparability of the groups will be assessed through independent ANOVAs (quantitative data) or Mantel-Haentzel and X2 tests (categorical data). Assuming comparability of groups across centers, the primary outcome, disease or treatment-related combined morbidity/mortality (for both intent-to-treat and per-protocol populations) will be compared between groups through a Fisher's Exact Test for independent proportions at 1, 5, and 10 years. Similar analyses will be done for disease or treatment-related mortality combined mortality-morbidity. Secondary outcomes and overall morbidity will be compared between groups through independent t-tests (quantitative variables) or X2 statistics (categorical data). The analyses of neurological data at follow-up will control for baseline data using logistic regression, ANOVA or Cox regression multivariate models. All tests will be interpreted with adjustment for multiplicity to have the 0.05 level of confidence at 10 years only. Finally, a logistic regression will be used to find baseline variables capable of predicting hemorrhages or complications in both groups. The method planned is a stepwise forward on a likelihood ratio with a probability of 0.05 to enter a predictor (PIN in) and a probability of 0.10 to exclude a predictor (PIN out). Possible predictors include the size of the aneurysm, location, patient age, status of the aneurysm and previous history of SAH versus unruptured only) as well as other baseline characteristics. All analyses of the primary endpoint will be performed taking into account the multiplicity of tests and any interim analyses. Secondary analyses will be performed using an alpha of 5%.

03

Conditions studied

  • Saccular Aneurysm
  • Intracranial Aneurysm
  • Unruptured Cerebral Aneurysm

Browse trials for

Keywords

  • Unruptured Intracranial Aneurysm
  • Endovascular treatment
  • Surgical treatment
  • Conservative management
04

In context

Intracranial Aneurysm Reclassified

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Compared within Intracranial Aneurysm, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aneurysm. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with at least one documented, intracranial subarachnoid aneurysm (cavernous aneurysms are excluded)

Exclusion criteria

Exclusion Criteria:

  • Patients with any intracranial hemorrhage, including SAH, within the previous 30 days
  • Patients with AVM-associated aneurysms
  • Patients unable to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Interventional Therapy

    Neurosurgery or Endovascular procedure

    Device: microsurgery; endovascular interventions

  • No intervention
    Conservative Management

    Monitoring with pharmacological therapy if need arises.

Interventions

  • Devicemicrosurgery; endovascular interventions

    microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both

07

What researchers measure

Primary outcomes

  1. Survival without neurological dependency

    Number of patients without neurological dependency. Neurological dependency is defined as an outcome with a modified Rankin Score greater or equal to 3

    Time frame: 10 years

Secondary outcomes

  1. Sub-arachnoid hemorrhage (SAH)

    Number of patients with an incidence of SAH and related morbidity and mortality

    Time frame: 10 years

  2. morbi/mortality related to interventions

    Number of patients with Morbidity or Mortality related to microsurgery of endovascular procedures

    Time frame: 1 year

  3. Overall mortality

    Number of patients dead from any cause

    Time frame: 1, 5 and 10 years

  4. Overall morbidity

    Number of patients with a modified Rankin Score greater or equal to 3

    Time frame: 1, 5 and 10 years

  5. Length of hospitalization

    Number of days spent in hospital for intervention

    Time frame: 10 years

  6. Discharge location other than Home

    Number of patients discharged to a location other than home after the intervention

    Time frame: 10 years

08

Study locations

6 of 6 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2035, 180 months after the start.

Of 59 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 134. This study's planned 180 months is above that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 7, 2019
StartActual
Jan 15, 2020
Primary completionEst.
Jan 2035
CompletionEst.
Jan 2036
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04155606
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Jan 15, 2020
Primary completion
Jan 2035 (estimated)
Completion
Jan 2036 (estimated)
Last update
Jul 28, 2025

Study contacts

Tim Darsaut, MD, MSc
Contact
tdarsaut@ualberta.ca
780-407-1440
Jean Raymond, MD
Contact
jean.raymond@umontreal.ca
514-890-8000 ext. 27235
Tim Darsaut, MD
principal investigator · Neurosurgeon University of Alberta Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion